Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,877 as of Thursday, June 19, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,663 issues advancing vs. 1,297 declining with 187 unchanged. The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Waters ( WAT), down 1.2%, and Agilent Technologies ( A), down 0.8%. Top gainers within the industry include Smith & Nephew ( SNN), up 1.2%, Stryker Corporation ( SYK), up 1.2%, Covidien ( COV), up 0.7% and Abbott Laboratories ( ABT), up 0.6%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Opko Health ( OPK) is one of the companies pushing the Health Services industry lower today. As of noon trading, Opko Health is down $0.20 (-2.1%) to $9.20 on average volume. Thus far, 902,459 shares of Opko Health exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $9.19-$9.34 after having opened the day at $9.29 as compared to the previous trading day's close of $9.40. Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.9 billion and is part of the health care sector. Shares are up 11.4% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.